Roche to refile subcutaneous Tecentriq application with FDA before year’s end on the back of manufacturing tweaks
Roche plans to file a new application to the FDA by the end of the year for its subcutaneous version of Tecentriq, a spokesperson told …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
